VISHEE recently disclosed in its investor relations activity record that the company is continuously intensifying the development of a picosecond laser treatment device with leading pulse width and single-pulse energy metrics. Clinical reports are expected to be obtained by the end of 2023, with registration to be submitted thereafter.
The company also acknowledged that the decline in the number of maternity patients has objectively led to a situation where the demand for postpartum rehabilitation in hospitals is not growing as rapidly as before. However, pelvic floor rehabilitation is a treatment method aimed at all people with pelvic floor disorders, including middle-aged and elderly women with needs in gynecology, urology, and proctology departments. Therefore, the overall patient population has not significantly decreased. In the field of pelvic floor rehabilitation, the company has expanded its development towards patients with pelvic floor dysfunction in both genders, showing a gradually stabilizing and improving trend. In the future, the company will continue to strengthen its promotional efforts in gynecology, urology, and proctology fields.